Sublingual immunotherapy for food allergy and its future directions

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Sicherer SH, Sampson HA. Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention and management. J. Allergy Clin. Immunol. 141(1), 41–58 (2018).
  Medline CASGoogle Scholar
• 2. Peters RL, Koplin JJ, Gurrin LC et al. The prevalence of food allergy and other allergic diseases in early childhood in a population-based study: healthNuts age 4-year follow-up. J. Allergy Clin. Immunol. 140(1), 145–153.e8 (2017).
  MedlineGoogle Scholar
• 3. Gupta RS, Warren CM, Smith BM et al. Prevalence and severity of food allergies among US adults. JAMA Netw. Open 2(1), e185630 (2019).
  MedlineGoogle Scholar
• 4. McGowan EC, Keet CA. Prevalence of self-reported food allergy in the National Health and Nutrition Examination Survey (NHANES) 2007–2010. J. Allergy Clin. Immunol. 132(5), 1216–1219.e5 (2013).
  MedlineGoogle Scholar
• 5. Prescott S, Allen KJ. Food allergy: riding the second wave of the allergy epidemic: the food allergy epidemic. Pediatr. Allergy Immunol. 22(2), 155–160 (2011).
  MedlineGoogle Scholar
• 6. Fleischer DM, Perry TT, Atkins D et al. Allergic reactions to foods in preschool-aged children in a prospective observational food allergy study. Pediatrics 130(1), e25–e32 (2012).
  MedlineGoogle Scholar
• 7. Stensgaard A, Bindslev-Jensen C, Nielsen D, Munch M, DunnGalvin A. Quality of life in childhood, adolescence and adult food allergy: patient and parent perspectives. Clin. Exp. Allergy 47(4), 530–539 (2017).
  Medline CASGoogle Scholar
• 8. Blom WM, Michelsen-Huisman AD, van Os-Medendorp H et al. Accidental food allergy reactions: products and undeclared ingredients. J. Allergy Clin. Immunol. 142(3), 865–875 (2018).
  MedlineGoogle Scholar
• 9. Versluis A, Knulst AC, Kruizinga AG et al. Frequency, severity and causes of unexpected allergic reactions to food: a systematic literature review. Clin. Exp. Allergy 45(2), 347–367 (2015).
  Medline CASGoogle Scholar
• 10. Avery NJ, King RM, Knight S, Hourihane JO. Assessment of quality of life in children with peanut allergy. Pediatr. Allergy Immunol. 14(5), 378–382 (2003).
  MedlineGoogle Scholar
• 11. Du Toit G, Roberts G, Sayre PH et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N. Engl. J. Med. 372(9), 803–813 (2015).
  MedlineGoogle Scholar
• 12. Perkin MR, Logan K, Tseng A et al. Randomized trial of introduction of allergenic foods in breast-fed infants. N. Engl. J. Med. 374(18), 1733–1743 (2016).
  Medline CASGoogle Scholar
• 13. Bégin P, Paradis L, Paradis J, Picard M, Des Roches A. Natural resolution of peanut allergy: a 12-year longitudinal follow-up study. J. Allergy Clin. Immunol. Pract. 1(5), 528–530.e4 (2013).
  MedlineGoogle Scholar
• 14. Fisher HR, Du Toit G, Bahnson HT, Lack G. The challenges of preventing food allergy. Ann. Allergy Asthma Immunol. 121(3), 313–319 (2018).
  MedlineGoogle Scholar
• 15. Nelson H, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract1. J. Allergy Clin. Immunol. 99(6), 744–751 (1997).
  Medline CASGoogle Scholar
• 16. Kim EH, Burks AW. Food allergy immunotherapy: OIT and EPIT. Allergy 75(6), 1337–1346 (2020).
  MedlineGoogle Scholar
• 17. Burks AW, Sampson HA, Plaut M, Lack G, Akdis CA. Treatment for food allergy. J. Allergy Clin. Immunol. 141(1), 1–9 (2018).
  MedlineGoogle Scholar
• 18. Dantzer JA, Wood RA. Next-generation approaches for the treatment of food allergy. Curr. Allergy Asthma Rep. 19(1), 5 (2019).
  MedlineGoogle Scholar
• 19. The PALISADE Group of Clinical Investigators. AR101 oral immunotherapy for peanut allergy. N. Engl. J. Med. 379(21), 1991–2001 (2018).
  MedlineGoogle Scholar
• 20. Voelker R. Drug approved to aid youths with peanut allergy. JAMA 323(9), 817 (2020).
  Google Scholar
• 21. Chu DK, Wood RA, French S et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet 393(10187), 2222–2232 (2019).
  Medline CASGoogle Scholar
• 22. Varshney P, Steele PH, Vickery BP et al. Adverse reactions during peanut oral immunotherapy home dosing. J. Allergy Clin. Immunol. 124(6), 1351–1352 (2009).
  MedlineGoogle Scholar
• 23. Jay DC, Nadeau KC. Immune mechanisms of sublingual immunotherapy. Curr. Allergy Asthma Rep. 14(11), 473 (2014).
  MedlineGoogle Scholar
• 24. Scadding G, Durham S. Mechanisms of sublingual immunotherapy. J. Asthma 46(4), 322–334 (2009).
  Medline CASGoogle Scholar
• 25. Allam J-P, Würtzen PA, Reinartz M et al. Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation and enhances their migratory and TGF-β1 and IL-10–producing properties. J. Allergy Clin. Immunol. 126(3), 638–645.e1 (2010).
  Medline CASGoogle Scholar
• 26. Allam J-P, Peng W-M, Appel T et al. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J. Allergy Clin. Immunol. 121(2), 368–374.e1 (2008).
  Medline CASGoogle Scholar
• 27. Scadding GW, Shamji MH, Jacobson MR et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells.. Clin. Exp. Allergy 40(4), 598–606 (2010).
  Medline CASGoogle Scholar
• 28. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C. Sublingual immunotherapy induces IL-10–producing T regulatory cells, allergen-specific T-cell tolerance and immune deviation. J. Allergy Clin. Immunol. 120(3), 707–713 (2007).
  Medline CASGoogle Scholar
• 29. Suárez-Fueyo A, Ramos T, Galán A et al. Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation. J. Allergy Clin. Immunol. 133(1), 130–138.e2 (2014).
  Medline CASGoogle Scholar
• 30. Nouri-Aria KT, Wachholz PA, Francis JN et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J. Immunol. 172(5), 3252–3259 (2004).
  Medline CASGoogle Scholar
• 31. Sánchez Acosta G, Kinaciyan T, Kitzmüller C, Möbs C, Pfützner W, Bohle B. IgE-blocking antibodies following SLIT with recombinant Mal d 1 accord with improved apple allergy. J. Allergy Clin. Immunol. S0091674920304188 doi: 10.1016/j.jaci.2020.03.015 (2020).
  MedlineGoogle Scholar
• 32. Dahl R, Kapp A, Colombo G et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J. Allergy Clin. Immunol. 121(2), 512–518.e2 (2008).
  Medline CASGoogle Scholar
• 33. Renand A, Shamji MH, Harris KM et al. Synchronous immune alterations mirror clinical response during allergen immunotherapy. J. Allergy Clin. Immunol. 141(5), 1750–1760.e1 (2018).
  Medline CASGoogle Scholar
• 34. Scadding GW, Calderon MA, Shamji MH et al. Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: the GRASS randomized clinical trial. JAMA 317(6), 615 (2017).
  Medline CASGoogle Scholar
• 35. Durham SR, Emminger W, Kapp A et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J. Allergy Clin. Immunol. 129(3), 717–725.e5 (2012).
  MedlineGoogle Scholar
• 36. Mempel M, Rakoski J, Ring J, Ollert M. Severe anaphylaxis to kiwi fruit: immunologic changes related to successful sublingual allergen immunotherapy. J. Allergy Clin. Immunol. 111(6), 1406–1409 (2003).
  MedlineGoogle Scholar
• 37. Kerzl R, Simonowa A, Ring J, Ollert M, Mempel M. Life-threatening anaphylaxis to kiwi fruit: protective sublingual allergen immunotherapy effect persists even after discontinuation. J. Allergy Clin. Immunol. 119(2), 507–508 (2007).
  MedlineGoogle Scholar
• 38. Enrique E, Pineda F, Malek T et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J. Allergy Clin. Immunol. 116(5), 1073–1079 (2005).
  Medline CASGoogle Scholar
• 39. Fernández-Rivas M, Garrido Fernández S, Nadal JA et al. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy 64(6), 876–883 (2009).
  Medline CASGoogle Scholar
• 40. Kinaciyan T, Nagl B, Faustmann S et al. Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen–related apple allergy. J. Allergy Clin. Immunol. 141(3), 1002–1008 (2018).
  Medline CASGoogle Scholar
• 41. Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J. Allergy Clin. Immunol. 129(2), 448–455.e5 (2012). • Only study to compare outcomes and side effects between oral immunotherapy and sublingual immunotherapy (SLIT) in treatment of milk allergy.
  Medline CASGoogle Scholar
• 42. Fleischer DM, Burks AW, Vickery BP et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J. Allergy Clin. Immunol. 131(1), 119–127.e7 (2013). •• First randomized controlled trial of SLIT for the treatment of peanut allergy.
  Medline CASGoogle Scholar
• 43. Burks AW, Wood RA, Jones SM et al. Sublingual immunotherapy for peanut allergy: long-term follow-up of a randomized multicenter trial. J. Allergy Clin. Immunol. 135(5), 1240–1248.e3 (2015).
  Medline CASGoogle Scholar
• 44. Burks AW, Jones SM, Wood RA et al. Oral Immunotherapy for treatment of egg allergy in children. N. Engl. J. Med. 367(3), 233–243 (2012).
  Medline CASGoogle Scholar
• 45. Narisety SD, Frischmeyer-Guerrerio PA, Keet CA et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J. Allergy Clin. Immunol. 135(5), 1275–1282.e6 (2015). • Randomized controlled trial comparing SLIT and oral immunotherapy in treatment of peanut allergy.
  Medline CASGoogle Scholar
• 46. Kim EH, Bird JA, Kulis M et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J. Allergy Clin. Immunol. 127(3), 640–646.e1 (2011).
  Medline CASGoogle Scholar
• 47. Kim EH, Yang L, Ye P et al. Long-term sublingual immunotherapy for peanut allergy in children: clinical and immunologic evidence of desensitization. J. Allergy Clin. Immunol. 144(5), 1320–1326.e1 (2019). •• Randomized controlled trial of SLIT for the treatment of peanut allergy in young children.
  Medline CASGoogle Scholar
• 48. Vickery BP, Scurlock AM, Kulis M et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J. Allergy Clin. Immunol. 133(2), 468–475.e6 (2014).
  Medline CASGoogle Scholar
• 49. Greenhawt M, Marsh R, Gilbert H, Sicherer S, DunnGalvin A, Matlock D. Understanding caregiver goals, benefits and acceptable risks of peanut allergy therapies. Ann. Allergy Asthma Immunol. 121(5), 575–579 (2018). • Detailed report of caregiver goals and expectations of food allergy therapy.
  MedlineGoogle Scholar
• 50. Baumert JL, Taylor SL, Koppelman SJ. Quantitative assessment of the safety benefits associated with increasing clinical peanut thresholds through immunotherapy. J. Allergy Clin. Immunol. Pract. 6(2), 457–465.e4 (2018).
  MedlineGoogle Scholar
• 51. Virkud YV, Burks AW, Steele PH et al. Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy. J. Allergy Clin. Immunol. 139(3), 882–888.e5 (2017). • Retrospective analysis of adverse effects of oral immunotherapy.
  MedlineGoogle Scholar
• 52. Passalacqua G, Nowak-Węgrzyn A, Canonica GW. Local side effects of sublingual and oral immunotherapy. J. Allergy Clin. Immunol. Pract. 5(1), 13–21 (2017).
  MedlineGoogle Scholar
• 53. Kiel MA, Röder E, Gerth van Wijk R, Al MJ, Hop WCJ, Rutten-van Mölken MPMH. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J. Allergy Clin. Immunol. 132(2), 353–360.e2 (2013).
  MedlineGoogle Scholar
• 54. Incorvaia C, Mauro M, Leo G, Ridolo E. Adherence to sublingual immunotherapy. Curr. Allergy Asthma Rep. 16(2), 12 (2016).
  MedlineGoogle Scholar
• 55. Savi E, Peveri S, Senna G, Passalacqua G. Causes of SLIT discontinuation and strategies to improve the adherence: a pragmatic approach. Allergy 68(9), 1193–1195 (2013).
  Medline CASGoogle Scholar
• 56. Reisacher WR, Suurna MV, Rochlin K, Bremberg MG, Tropper G. Oral mucosal immunotherapy for allergic rhinitis: a pilot study. Allergy Rhinol. 7(1), 21–28 (2016).
  MedlineGoogle Scholar
• 57. Allam J-P, Stojanovski G, Friedrichs N et al. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy 63(6), 720–727 (2008).
  MedlineGoogle Scholar
• 58. Cox LS, Hankin C, Lockey R. Allergy immunotherapy adherence and delivery route: location does not matter. J. Allergy Clin. Immunol. Pract. 2(2), 156–160.e2 (2014).
  MedlineGoogle Scholar